Literature DB >> 25170397

Incorporating GSA-SPECT into CT-based dose-volume histograms for advanced hepatocellular carcinoma radiotherapy.

Shintaro Shirai1, Morio Sato1, Yasutaka Noda1, Yoshitaka Kumayama1, Noritaka Shimizu1.   

Abstract

In single photon emission computed tomography-based three-dimensional radiotherapy (SPECT-B-3DCRT), images of Tc-99m galactosyl human serum albumin (GSA), which bind to receptors on functional liver cells, are merged with the computed tomography simulation images. Functional liver is defined as the area of normal liver where GSA accumulation exceeds that of hepatocellular carcinoma (HCC). In cirrhotic patients with a gigantic, proton-beam-untreatable HCC of ≥ 14 cm in diameter, the use of SPECT-B-3DCRT in combination with transcatheter arterial chemoembolization achieved a 2-year local tumor control rate of 78.6% and a 2-year survival rate of 33.3%. SPECT-B-3DCRT was applied to HCC to preserve as much functional liver as possible. Sixty-four patients with HCC, including 30 with Child B liver cirrhosis, received SPECT-B-3DCRT and none experienced fatal radiation-induced liver disease (RILD). The Child-Pugh score deteriorated by 1 or 2 in > 20% of functional liver volume that was irradiated with ≥ 20 Gy. The deterioration in the Child-Pugh score decreased when the radiation plan was designed to irradiate ≤ 20% of the functional liver volume in patients given doses of ≥ 20 Gy (FLV20Gy). Therefore, FLV20Gy ≤ 20% may represent a safety index to prevent RILD during 3DCRT for HCC. To supplement FLV20Gy as a qualitative index, we propose a quantitative indicator, F 20Gy, which was calculated as F 20Gy = 100% × (the GSA count in the area irradiated with ≥ 20 Gy)/(the GSA count in the whole liver).

Entities:  

Keywords:  Dose-volume histogram; Functional image-guided radiotherapy; Galactosyl human serum albumin; Hepatocellular carcinoma; Three-dimensional radiotherapy

Year:  2014        PMID: 25170397      PMCID: PMC4147440          DOI: 10.4329/wjr.v6.i8.598

Source DB:  PubMed          Journal:  World J Radiol        ISSN: 1949-8470


  24 in total

1.  Incorporation of functional status into dose-volume analysis.

Authors:  L B Marks; G W Sherouse; M T Munley; G C Bentel; D P Spencer
Journal:  Med Phys       Date:  1999-02       Impact factor: 4.071

2.  Radiation dose-effect relations and local recovery in perfusion for patients with non-small-cell lung cancer.

Authors:  Y Seppenwoolde; S H Muller; J C Theuws; P Baas; J S Belderbos; L J Boersma; J V Lebesque
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-06-01       Impact factor: 7.038

3.  The incorporation of SPECT functional lung imaging into inverse radiotherapy planning for non-small cell lung cancer.

Authors:  Judith A Christian; Mike Partridge; Elena Nioutsikou; Gary Cook; Helen A McNair; Bernadette Cronin; Frederic Courbon; James L Bedford; Michael Brada
Journal:  Radiother Oncol       Date:  2005-11-07       Impact factor: 6.280

4.  Risk factors for recurrence of large HCC in patients treated by combined TAE and PEI.

Authors:  S Arata; K Tanaka; H Okazaki; M Kondo; M Morimoto; S Saito; K Numata; S Nakamura; H Sekihara
Journal:  Hepatogastroenterology       Date:  2001 Mar-Apr

5.  Surgical intervention for patients with stage IV-A hepatocellular carcinoma without lymph node metastasis: proposal as a standard therapy.

Authors:  I Ikai; Y Yamaoka; Y Yamamoto; N Ozaki; Y Sakai; S Satoh; N Shinkura; M Yamamoto
Journal:  Ann Surg       Date:  1998-03       Impact factor: 12.969

6.  Local radiotherapy for patients with unresectable hepatocellular carcinoma.

Authors:  Won Park; Do Hoon Lim; Seung Woon Paik; Kwang Cheol Koh; Moon Seok Choi; Cheol Keun Park; Byung Chul Yoo; Jeong Eun Lee; Min Kyu Kang; Young Je Park; Hee Rim Nam; Yong Chan Ahn; Seung Jae Huh
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-03-15       Impact factor: 7.038

7.  Hyperasialoglycoproteinemia in patients with chronic liver diseases and/or liver cell carcinoma. Asialoglycoprotein receptor in cirrhosis and liver cell carcinoma.

Authors:  T Sawamura; H Nakada; H Hazama; Y Shiozaki; Y Sameshima; Y Tashiro
Journal:  Gastroenterology       Date:  1984-12       Impact factor: 22.682

8.  Proton beam therapy for large hepatocellular carcinoma.

Authors:  Shinji Sugahara; Yoshiko Oshiro; Hidetsugu Nakayama; Kuniaki Fukuda; Masashi Mizumoto; Masato Abei; Junichi Shoda; Yasushi Matsuzaki; Eriko Thono; Mari Tokita; Koji Tsuboi; Koichi Tokuuye
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-05-07       Impact factor: 7.038

9.  [The utility of quantitative 99mTc-GSA liver scintigraphy in the evaluation of hepatic functional reserve: comparison with 99mTc-PMT and 99mTc-Sn colloid].

Authors:  N Shuke; T Aburano; K Nakajima; K Yokoyama; B F Sun; H Matsuda; A Muramori; T Michigishi; N Tonami; K Hisada
Journal:  Kaku Igaku       Date:  1992-05

10.  Feasibility and efficacy of single photon emission computed tomography-based three-dimensional conformal radiotherapy for hepatocellular carcinoma 8 cm or more with portal vein tumor thrombus in combination with transcatheter arterial chemoembolization.

Authors:  Shintaro Shirai; Morio Sato; Kazuhiro Suwa; Kazushi Kishi; Chigusa Shimono; Tetsuo Sonomura; Nobuyuki Kawai; Hirohiko Tanihata; Hiroki Minamiguchi; Motoki Nakai
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-06-18       Impact factor: 7.038

View more
  2 in total

1.  Differential hepatic avoidance radiation therapy: Proof of concept in hepatocellular carcinoma patients.

Authors:  Stephen R Bowen; Jatinder Saini; Tobias R Chapman; Robert S Miyaoka; Paul E Kinahan; George A Sandison; Tony Wong; Hubert J Vesselle; Matthew J Nyflot; Smith Apisarnthanarax
Journal:  Radiother Oncol       Date:  2015-04-28       Impact factor: 6.280

2.  Functional Liver Imaging in Radiotherapy for Liver Cancer: A Systematic Review and Meta-Analysis.

Authors:  Pi-Xiao Zhou; Ying Zhang; Quan-Bin Zhang; Guo-Qian Zhang; Hui Yu; Shu-Xu Zhang
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.